Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

CRISPR stocks

Ready to invest in the gene editing industry? Consider these 7 stocks.

The best CRISPR stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

7 CRISPR stocks to watch

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

  1. Crispr Therapeutics (CRSP)
  2. Editas Medicine (EDIT)
  3. Regeneron Pharmaceuticals (REGN)
  4. Cellectis (CLLS)
  5. Beam Therapeutics Inc (BEAM)
  6. Bluebird bio (BLUE)
  7. Sangamo Therapeutics (SGMO)

Compare trading platforms

Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in CRISPR stocks.
1 - 5 of 5
Name Product Asset types Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Take a deeper dive into CRISPR stocks

If you're interested in investing in the gene editing industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.

1. Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Crispr Therapeutics stock opened the day at $61.11 after a previous close of $60.77. The latest price was $63.79 (25-minute delay). Crispr Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD915.4 million and employs 473 staff.

  • Market capitalization: $5,186,527,744
  • P/E ratio: 17.3516
  • PEG ratio: 0

Back to top


2. Editas Medicine (EDIT)

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.

Editas Medicine stock opened the day at $56.09 after a previous close of $56.52. The latest price was $54.90 (25-minute delay). Editas Medicine is listed on the NASDAQ, has a trailing 12-month revenue of around USD$25.8 million and employs 264 staff.

  • Market capitalization: $812,024,256
  • PEG ratio: 0

Back to top


3. Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Regeneron Pharmaceuticals stock opened the day at $587.76 after a previous close of $591.13. The latest price was $595.40 (25-minute delay). Regeneron Pharmaceuticals is listed on the NASDAQ, has a trailing 12-month revenue of around USD$16.5 billion and employs 10,492 staff.

  • Market capitalization: $67,279,577,088
  • P/E ratio: 8.7119
  • PEG ratio: 5.1144

Back to top


4. Cellectis (CLLS)

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants.

Cellectis stock opened the day at $15.14 after a previous close of $14.44. The latest price was $15.78 (25-minute delay). Cellectis is listed on the NASDAQ, has a trailing 12-month revenue of around USD$41.4 million and employs 294 staff.

  • Market capitalization: $122,370,256
  • PEG ratio: 0

Back to top


5. Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.

Beam Therapeutics Inc stock opened the day at $100.64 after a previous close of $98.05. The latest price was $100.99 (25-minute delay). Beam Therapeutics Inc is listed on the NASDAQ, has a trailing 12-month revenue of around USD$60.3 million and employs 394 staff.

  • Market capitalization: $2,795,916,032

Back to top


6. Bluebird bio (BLUE)

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Bluebird bio stock opened the day at $30.43 after a previous close of $30.43. The latest price was $30.57 (25-minute delay). Bluebird bio is listed on the NASDAQ, has a trailing 12-month revenue of around USD$4.7 million and employs 518 staff.

  • Market capitalization: $305,821,824
  • PEG ratio: 0.32

Back to top


7. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Sangamo Therapeutics stock opened the day at $12.01 after a previous close of $12.01. The latest price was $11.71 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$112.7 million and employs 431 staff.

  • Market capitalization: $627,820,416
  • PEG ratio: 0

Back to top

How to buy CRISPR stocks

Sign up with an online broker or platform to invest in one or more of these CRISPR stocks.

  1. Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
  2. Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
  3. Search for the stock you're interested in. Find the stock by name or ticker symbol, like CRSP or EDIT.
  4. Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
  5. Choose an order type. Invest in the CRISPR stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
  6. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the gene editing industry, track how your stock performs to decide when it’s time to sell.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Bottom line

While it’s possible to turn a profit investing in CRISPR stocks, keep in mind that — like any investment — CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the gene editing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site